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Background: Periostin, an extracellular matrix protein, contributes to subepithelial 49 
thickening in asthmatic airways, and its serum levels reflect airway eosinophilic 50 
inflammation. However, the relationship between periostin and the development of airflow 51 
limitation, a functional consequence of airway remodeling, remains unknown. 52 
Objective: To determine the relationship between serum periostin levels and 53 
pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. 54 
Methods: 224 asthmatic patients (average age 62.3 years) treated with ICS for at least 55 
4 years were enrolled. Annual changes in forced expiratory volume in one second (FEV1), 56 
from at least one year after the initiation of ICS treatment to the time of enrollment or later 57 
(average 16.2 measurements over 8 years per individual), were assessed. At enrollment, 58 
clinical indices, biomarkers including serum periostin, and periostin gene polymorphisms 59 
were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 60 
30 mL·yr
-1
 or greater were analyzed. 61 
Results: High serum periostin levels (≥ 95 ng/mL) at enrollment, the highest treatment 62 
step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or 63 
a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL·yr
-1
 or 64 
greater. Multivariate analysis revealed that high serum periostin, the highest treatment step, 65 
and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin 66 
gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 67 
mL·yr
-1
 or greater (rs9603226). 68 
Conclusions: Serum periostin appears to be a useful biomarker for the development of 69 
airflow limitation in asthmatic patients on ICS. 70 
 71 
Clinical implications (25 words) 72 
Serum periostin levels reflect greater FEV1 decline in asthmatic patients on inhaled 73 
4 
 
corticosteroid treatment. POSTN gene polymorphisms may also be helpful for identifying 74 
rapid FEV1 decliners. 75 
Key words 76 
Asthma, inhaled corticosteroids, lung function decline, periostin, POSTN gene polymorphism, 77 
sinusitis, treatment step 78 
 79 
Abbreviations 80 
ACT: asthma control test 81 
ECP: eosinophil cationic protein 82 
FAS I: fasciclin I 83 
FEV1: forced expiratory volume in one second 84 
FVC: forced vital capacity 85 
hsCRP: high sensitivity C-reactive protein 86 
ICS: inhaled corticosteroids 87 
IgE: immunoglobulin E 88 
IL: interleukin 89 
ROC: receiver operating characteristic 90 
SNP: single-nucleotide polymorphism 91 
TGF-β: transforming growth factor beta 92 
 93 
Total word counts for the text and the abstract are 3800 and 258 words, respectively.94 
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Capsule summary (32 words) 95 
This is the first study to identify a relationship between high serum periostin and greater 96 





Airway inflammation and remodeling are key features of asthma that have been 100 
demonstrated by pathological
1
 and radiological findings
2,3
. Physiologically, patients with 101 
asthma show a greater decline in pulmonary function than subjects without asthma
4
. Studies 102 
that were mostly conducted in the era before inhaled corticosteroids (ICS) demonstrated that 103 




, and smoking 104 
history
4, 8
 were moderate to strong risk factors for greater decline in pulmonary function
5
. 105 
Blood and sputum eosinophilia
9, 10
 and genetic predisposition
11-13
 were also potential risk 106 
factors. Owing to early intervention with ICS, however, airway inflammation and the degree 107 
of annual decline in pulmonary function have been attenuated in a majority of asthmatic 108 
patients
14-16
. Meanwhile, a subset of patients still show accelerated decline in FEV1 and 109 
develop irreversible airway obstruction despite adequate treatment
17, 18
. van Veen et al. found 110 
that exhaled nitric oxide of 20 ppb or higher is a predictor of accelerated decline in 111 
pulmonary function in patients with difficult-to-treat asthma
18
. However, other biomarkers for 112 
greater decline in FEV1 despite treatment with ICS remain unknown. 113 
The airway inflammation of asthma is classically characterized by infiltration and 114 
activation of eosinophils, mast cells, and Th2 cells with several mediators and Th2 cytokines, 115 
such as interleukin (IL)-4, IL-5, and IL-13
19, 20
. Periostin, a secreted, 90-kDa, extracellular 116 
matrix protein that is induced by IL-4 and IL-13, was originally isolated as an osteoblast-117 
specific factor; it shares structural homology to the insect cell adhesion molecule fasciclin I 118 
(FAS I) and binds to fibronectin, tenascin-C, and collagen
21, 22
. In airway epithelial cells 119 
collected from patients with asthma, periostin is one of the up-regulated genes
23
, and its 120 
expression is correlated with thickness of the airway basement membrane
24
. Takayama et al. 121 
clearly demonstrated that periostin is deposited in the airway subepithelial layer in asthmatic 122 
patients. Moreover, serum periostin is identified as the single best predictor of airway 123 





. Therefore, we hypothesized that periostin would be a novel biomarker of 125 
Th2/eosinophil-driven airway inflammation and greater decline in pulmonary function, a 126 
functional consequence of airway remodeling in patients with asthma. 127 
 In this study, the effects of biomarkers and clinical indices on greater annual decline 128 
in pulmonary function in asthmatic patients on ICS treatment were examined, with the 129 
specific aim of determining the association between serum periostin levels and pulmonary 130 
function decline. Polymorphisms of the POSTN gene, which encodes periostin, were also 131 





For full details see Online Repository 135 
Patients 136 
     Patients with asthma were recruited from nine institutions belonging to the Kinki 137 
Hokuriku Airway disease Conference where asthma specialists manage patients. Asthma was 138 
diagnosed according to the American Thoracic Society criteria
26
. From September 2009 to 139 
December 2011, patients were enrolled if they had received ICS treatment for 4 years or more, 140 
undergone three or more pulmonary function tests when they were stable, and were free from 141 
exacerbations for at least one month. The first pulmonary function test was performed at least 142 
one year after the commencement of ICS treatment and at 25 years of age or older. Patients 143 
who had smoked more than 10 pack-years, smoked in the past one year, or had other 144 
pulmonary diseases were excluded. 145 
 This study was approved by the ethics committee of each participant institution and 146 
was registered in the UMIN Clinical Trials Registry (Registry ID UMIN000002414). Written 147 
informed consent was obtained from all participants. 148 
 149 
Measurements 150 
At enrollment, patients underwent a work-up that included answering a self-151 
completed questionnaire, spirometry, and blood tests. After enrollment, spirometry was 152 
repeated at least 6 months later for up to 12 months. 153 
 154 
Self-completed questionnaire and clinical indices 155 
 The self-completed questionnaire was composed of 4 major items, as presented in 156 
Table 1. The Asthma Control Test (ACT)™ was also scored. The treatment step at enrollment 157 






Pulmonary function 160 
Spirometry was performed using an electrical spirometer, which was calibrated once a 161 
week, at each institution. Spirometry data were obtained only when patients were stable. To 162 
determine pulmonary function on daily medications, ICS and other controllers, including 163 
long-acting β2 agonists, leukotriene receptor antagonists, or slow-release theophylline, were 164 
not withdrawn before spirometry. 165 
 166 
Measurement of systemic biomarkers 167 
Blood eosinophil and neutrophil counts, and serum levels of total immunoglobulin E 168 
(IgE), specific IgE against common inhaled allergens, eosinophil cationic protein (ECP), high 169 
sensitivity C-reactive protein (hsCRP), and periostin were determined. 170 
Serum periostin levels were measured using an enzyme-linked immunosorbent assay at 171 
Shino-test (Kanagawa, Japan), as described previously
28
. Pooled serum periostin level data 172 
from 66 healthy subjects [mean (SD), 60.7 (16.7) years old, 40 males]
28,29
 were used for 173 
comparison with those of asthmatic patients. 174 
 175 
Haplotype analysis, DNA extraction, and genotyping of the POSTN gene 176 
A total of 47 single-nucleotide polymorphisms (SNPs) in the region of the POSTN gene 177 
and its upstream, total 39 kb, was captured in the HapMap Japanese data set. Haplotype 178 
analysis identified 4 major haplotypes and 2 minor haplotypes. Two minor haplotypes were 179 
grouped into the closest major haplotype, and 3 tag SNPs that determined the 4 haplotypes 180 
were identified (Figure 1).  181 
Genomic DNA was isolated from blood cells using a QIAamp DNA Blood Mini Kit 182 
(Qiagen, Tokyo, Japan). SNPs were genotyped using a Taqman genotyping assay according 183 
to the manufacturer’s instructions (Applied Biosystems, Tokyo, Japan) and analyzed using an 184 




Statistical analysis 187 
Statistical analyses were performed using JMP version 9.0 (SAS Institute Inc., Tokyo, 188 
Japan). Annual changes in FEV1 (ΔFEV1) were estimated for each subject by fitting a least-189 
square regression line to all of his/her all available data points. Receiver operating 190 
characteristic (ROC) curve analysis was performed to determine a serum periostin cut-off 191 
value for asthmatic patients. The effects of serum biomarkers or other indices on ΔFEV1 were 192 
estimated using a generalized linear mixed model with adjustment for sex, height, age at 193 
enrollment, and FEV1 at the first measurement. The institutions were included as random 194 
effects in this model. On univariate analysis of ΔFEV1, the adjusted p value, i.e., q value, 195 
which was a measure of significance in terms of the false discovery rate, was obtained using 196 
R and QVALUE software
30 
to determine spurious significance in multiple testing. The effects 197 




 were similarly 198 
estimated using a generalized linear mixed model by IBM SPSS Advanced Statistics 19 199 
(SPSS Inc., Tokyo, Japan). Multivariate analysis was performed using variables with p < 0.10 200 
on univariate analysis, except for ICS daily maintenance dose because of its strong 201 
correlation with treatment step. On multivariate analysis, the periostin level was considered 202 
as a dichotomous variable (high or low) instead of a continuous variable. Correlation 203 
coefficients between serum periostin levels and clinical indices were estimated by fitting 204 
least-square regression lines to data, in which institutions were included as random effects. 205 
Unpaired t- and Chi-square tests were performed for comparisons of continuous and 206 
dichotomous variables, respectively. When data were not normally distributed, they were log-207 




Patients’ characteristics 210 
Initially, 233 patients were enrolled in this study, but 9 patients were excluded: 5 with a 211 
smoking history of more than 10 pack-years and 4 who did not have enough pulmonary 212 
function data available. The demographic data of the remaining 224 patients are presented in 213 
Table 2. The mean age at enrollment was 62.3 (13.7) years. Overall, 130 (58%) had onset of 214 
asthma at 40 years or older. The average number of measurements of FEV1, follow-up period, 215 
and ΔFEV1 of 224 patients were 16.2 (13.9) times, 8.0 (4.5) years, and -7.8 (34.6) mL‧yr
-1
, 216 
respectively. The distribution of ΔFEV1 in this population is shown in Figure E1 in the Online 217 
Repository. Within 2 years after diagnosis, 46% of patients started ICS treatment. At 218 
enrollment, 82% of patients took controllers such as long-acting β2 agonists, leukotriene 219 
receptor antagonists, or sustained release theophylline to achieve adequate asthma control. 220 
Based on a questionnaire, adherence to medication was satisfactory; 49% of the participants 221 
never and 38% seldom forgot to take ICS or other medications. Based on ACT scores, 50% 222 
was totally controlled, and 38% scored from 20 to 24, indicating that they were well 223 
controlled at enrollment. 224 
Serum periostin levels of asthmatic patients [92.8 (38.4) ng/mL] were significantly 225 
higher than those of healthy subjects [39.1 (24.5) ng/mL, p < 0.001]. The ROC curve analysis 226 
was performed to discriminate patients with asthma who were thought to have refractory Th2 227 
inflammation despite long-term ICS treatment from healthy subjects. The highest specificity 228 
among the 4 cut-off values tested was achieved at 95 ng/mL (0.985) in the comparison study 229 
of 224 asthmatic patients and 66 healthy subjects. Therefore a cut-off value of  95 ng/mL was 230 
used to define a high serum periostin group, although it had relatively lesser sensitivity 231 
(0.379) (see Figure E2 in the Online Repository). In asthmatic patients, 85 patients (38%) had 232 
high serum periostin levels (≥ 95 ng/mL). Of the 85 patients, 40 patients (47%) were on 233 
12 
 
treatment step 4, according to the treatment step classification
27
, and 9 patients (11%) were 234 
on treatment step 5.  235 
 236 
Associations between serum periostin levels and greater annual decline in FEV1 and a 237 
decline in FEV1 of 30 mL∙yr
-1
 or greater 238 
In an analysis of continuous values of ΔFEV1, greater decline in FEV1 was associated 239 
with higher serum periostin levels at enrollment, treatment step 5, lower ACT scores, 240 
incomplete adherence to medications, comorbid or a history of sinusitis, and comorbid 241 
diabetes mellitus (Table 3). When patients were stratified into two groups according to their 242 
serum periostin levels, high serum periostin (≥ 95 ng/mL) was also associated with greater 243 
decline in FEV1 (Table 3). Of these, high serum periostin was significant after controlling for 244 
multiple testing using the false discovery rate (q = 0.03, data not shown in Table 3).
30
 245 
Multivariate analysis revealed that greater decline of FEV1 was solely associated with high 246 
serum periostin (≥ 95 ng/mL) (estimated effect -5.39, 95% confidence interval -10.0 to -0.77, 247 
p = 0.02). 248 
Fifty-two patients (23%) showed a decline in FEV1 of 30 mL∙yr
-1
 or greater [mean -249 
51.8 (18.4) mL‧yr-1] and were considered rapid decliners31. When adjusted by confounders, 250 
higher serum periostin levels at enrollment, treatment step 5, a history of admission due to 251 
asthma exacerbation, higher ICS daily doses, comorbid or a history of sinusitis, and ex-252 
smoking were associated with a decline in FEV1 of 30 mL∙yr
-1
 or greater. High serum 253 
periostin (≥ 95 ng/mL) was also associated with a decline in FEV1 of 30 mL∙yr
-1
 or greater 254 
(Table 4). On multivariate analysis, high serum periostin (≥ 95 ng/mL), treatment step 5, and 255 
ex-smoking were independent risk factors for a decline in FEV1 of 30 mL∙yr
-1
 or greater 256 
(Table 4). 257 
Of the 224 patients, 19 patients were on treatment step 5, and 36 patients took high-258 
dose ICS (1,000 μg or higher doses of ICS equivalent to fluticasone propionate daily). When 259 
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patients were stratified into the high periostin group, the average ΔFEV1 of patients on 260 
treatment step 5 (n = 9) was -41.0 (49.3) mL‧yr-1, and 7 of them (78%) had excess decline; 261 
the average ΔFEV1 of patients on high-dose ICS (n=18) was -34.3 (39.4) mL‧yr
-1
, and 11 of 262 
them (61%) had a decline in FEV1 of 30 mL∙yr
-1
 or greater. 263 
 264 
Serum periostin levels and clinical indices 265 
     In 224 patients, serum periostin levels were weakly associated with blood 266 
eosinophil counts (Figure 2), serum IgE (Figure 2) and ECP levels (r = 0.25, p = 0.0005), 267 
ICS-untreated period, i.e. period between onset of asthma and the initiation of ICS therapy (r 268 
= 0.16, p = 0.01), daily maintenance doses of ICS at enrollment (r = 0.13, p = 0.05), and a 269 
history of admission due to asthma exacerbation (r = 0.15, p = 0.03). Serum periostin levels 270 
were significantly higher in patients on high-dose ICS (≥ 1,000 μg daily) than in the 271 
remaining patients (110.3 ng/mL vs. 89.5 ng/mL, p = 0.003). Lastly, serum periostin levels 272 
were higher in patients with sinusitis than in those without sinusitis (103.9 ng/mL vs. 88.3 273 
ng/mL, p = 0.007). Serum periostin levels did not show any seasonal variability or 274 
association with age at onset of asthma (data not shown).   275 
 276 
POSTN gene polymorphisms 277 
Associations between polymorphisms of the POSTN gene, which encodes periostin, 278 
and both serum periostin levels and pulmonary function decline were then investigated. In 279 
one patient, DNA quality was insufficient for genotyping; thus, 3 tag SNPs of the POSTN 280 
gene were analyzed in 223 patients. All genotyped data were in Hardy-Weinberg equilibrium. 281 
The frequencies of the 3 tag SNPs and analysis results using dominant and recessive models 282 
for serum periostin levels and a decline in FEV1 of 30 mL∙yr
-1
 or greater are presented in 283 
Table 5. 284 
Serum periostin levels were higher in patients with the GG genotype of rs3829365 than 285 
14 
 
in those with the GC/CC genotype (GG 98.7 ng/mL vs. GC/CC 86.1 ng/mL, p = 0.003). 286 
rs1028728 was not associated with serum periostin levels or with the frequency of rapid 287 
decliners, but patients with the TT genotype of rs1028728, 4 patients only, showed no 288 
significant decline compared with the AA/AT genotype (AA/AT -8.6 mL･yr-1 vs. TT 29.3 289 
mL･yr-1, p = 0.03). Rapid decliners were more frequently observed in patients with the minor 290 
A allele of rs9603226 than in the GG genotype (GG 16% vs. AG/AA 30%, p = 0.02). A 291 
marked difference in the frequency of rapid decliners was observed when patients were 292 
stratified into the high periostin group [GG of rs9630226 (n = 37) 19% vs. AG/AA (n =47) 293 




To the best of our knowledge, this is the first study to identify a relationship between 296 
greater decline in FEV1 and higher serum periostin levels, particularly if they were 95 ng/mL 297 
or more, in asthmatic patients on ICS treatment. It was also shown that high serum periostin, 298 
together with treatment step 5 and light ex-smoking, was an independent risk factor for a 299 
decline in FEV1 of 30 mL∙yr
-1
 or greater. In addition, polymorphisms of the POSTN gene, 300 
which encodes periostin, were associated with serum periostin levels and a decline in FEV1 301 
of 30 mL∙yr-1 or greater in asthmatic patients. These findings suggest that serum periostin 302 
may be a useful biomarker for the development of airflow limitation in asthmatic patients on 303 
ICS. 304 
In this study, despite long-term treatment with ICS with or without other controllers, 305 
23% of asthmatic patients were rapid decliners who showed a decline in FEV1 of 30 mL·yr
-1
 306 
or greater, for which treatment step 5 was an independent risk factor. Adherence to ICS 307 
treatment and the frequency of early intervention with ICS did not differ between rapid 308 
decliners and non-decliners, although long-term adherence to ICS was undetermined in the 309 
present study. In previous studies of patients who were not treated with ICS, severe 310 
exacerbation of asthma contributed to greater annual decline of pulmonary function
6,7
, but the 311 
exacerbation-related greater annual decline disappeared in an early intervention group with 312 
ICS treatment in the START study
6
, which might be interpreted to mean that asthmatic 313 
patients on ICS treatment have little risk of accelerated FEV1 decline. However, since the 314 
START study originally recruited mild persistent asthmatic patients, its results cannot simply 315 
be applied to severe asthmatic patients. As observed in the present study, there would be a 316 
subset of asthmatic patients still at risk of greater annual decline of pulmonary function 317 
despite intensive treatment for asthma. 318 
Persistent eosinophilic airway inflammation is a key process in irreversible airway 319 
obstruction
10
. Indeed, exhaled nitric oxide of 20 ppb or higher is a risk factor for accelerated 320 
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FEV1 decline in patients with difficult-to-treat asthma
18
. Studies on novel therapies for 321 
refractory eosinophilic asthma, i.e., anti-IL-5 therapy
32
 and anti-IL-13 therapy
33
, revealed that 322 
these treatments may reverse airway remodeling when patients are adequately targeted, 323 
suggesting the necessity of establishing “companion diagnostics” for this population. 324 
According to the most recent study, serum periostin is the single best biomarker reflecting 325 
sputum and tissue eosinophilia among several biomarkers, including blood eosinophils and 326 
exhaled nitric oxide
25
. In the current study, the serum periostin level, which was associated 327 
with the blood eosinophil count, was the sole biomarker that reflected greater decline in FEV1. 328 
Periostin is secreted by airway epithelial cells
23, 24
 and lung fibroblasts
21
 in response to IL-4 329 
and IL-13 and is thought to be secreted into the capillary vessels. Downstream of IL-13, 330 




, and steroid 331 
insensitivity
36




 by binding to 332 
collagen
37
 and activates TGF-β24. In the asthmatic airway, periostin is deposited in the 333 
subepithelial layer, colocalizing with collagens I, III, and V, fibronectin, tenascin-C, and 334 
periostin itself
21
, which indicates involvement of periostin in airway remodeling in asthma. 335 
Collectively, periostin may be a key molecule that links eosinophilic inflammation and 336 
remodeling via IL-13 in asthmatic airways. Further roles of periostin in allergic inflammation 337 
and remodeling in the airways remain undetermined because studies using periostin-deficient 338 
mice with acute allergen exposure have yielded conflicting findings
38-40
; one study showed 339 
that periostin facilitates eosinophil infiltration into the lung
38
, whereas two other studies
39, 40
 340 
suggested protective roles of periostin. Meanwhile, a recent study of a chronic mouse model 341 
of atopic dermatitis demonstrated periostin’s role in the chronicity of Th2 inflammation29.  342 
In the present study, patients on high-dose ICS showed higher serum periostin levels 343 
than the other patients. Although a longitudinal study is needed to determine responses of 344 
serum periostin levels to ICS treatment, we do not think that the high serum periostin levels 345 
in patients on high-dose ICS were induced by ICS treatment, because periostin expression in 346 
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the airway epithelium was decreased with ICS treatment
23
. Rather, the elevation of serum 347 
periostin in this population may reflect IL-13-mediated inflammation that is partly refractory 348 
to ICS, as was reported in a recent study by Jia and colleagues
25
. They showed that, in 349 
patients with severe asthma who were treated with high doses ICS (> 1000 µg daily), 350 
elevation of serum periostin levels was associated with persistent airway tissue eosinophilia, 351 
concluding that serum periostin is a systemic biomarker of airway eosinophilia refractory to 352 
high-dose ICS
25
. Providing further support, among patients with moderate to severe asthma 353 
who are inadequately controlled despite ICS treatment, patients with high serum periostin 354 
levels are likely to benefit from anti-IL-13 antibody, lebrikizumab, treatment
33
. The novelty 355 
of the present finding is that high serum periostin is an independent risk factor for greater 356 
decline in FEV1, providing the first evidence for the potential association between persistent 357 
Th2- or IL-13-driven inflammation refractory to ICS treatment and greater decline in FEV1, a 358 
functional consequence of airway remodeling.  359 
Needless to say, current smokers with asthma have more accelerated FEV1 decline
4
 than 360 
those not smoking, and current smoking impairs the therapeutic response to ICS or oral 361 
corticosteroids
41
. Meanwhile, smoking cessation improves their FEV1 levels
42
, and ex-362 
smokers with asthma with 10 pack-years or more show an intermediate response to short-363 
term oral corticosteroid treatment, between current smokers and never-smokers
41
. In the 364 
present study, rather unexpectedly, ex-smoking with 10 pack-years or less was still an 365 
independent risk factor for a decline in FEV1 of 30 mL∙yr
-1
 or greater. It should be recognized 366 
that even light ex-smoking increases the risk of airway remodeling in asthmatic patients on 367 
ICS, and its underlying mechanisms should be clarified. 368 
Chronic sinusitis is a well-known comorbidity with severe asthma
43, 44
. In the present 369 
study, rapid decliners were more frequently observed in asthmatic patients with sinusitis than 370 
those without sinusitis on univariate analysis, and their periostin levels were higher than in 371 
patients without sinusitis. In the present study, polypoid lesions in the sinuses were not 372 
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evaluated by otolaryngologists at enrollment. However, considering that periostin is up-373 
regulated in nasal polyp tissue in patients with chronic rhinosinusitis
45
, asthmatic patients 374 
with sinusitis may have had severe upper and lower airway inflammation with persistent 375 
increases in periostin expression, which may have resulted in a decline in FEV1 of 30 mL∙yr
-1
 376 
or greater. Periostin is a potential molecule that unifies sinusitis and severe asthma. 377 
Periostin is encoded on the POSTN gene, which is located on chromosome 13q13.3. 378 
rs3829365, which is located at the 5’UTR region that may contain sequences to regulate 379 
translation efficiency or mRNA stability, was associated with serum periostin levels. This 380 
finding suggests that, besides IL-13, a master regulator of periostin, genetic background 381 
partly determines periostin levels, although a replication study would be necessary to confirm 382 
this. The minor A allele of rs9603226, located 66 bp upstream of exon 21 in the C-terminal 383 
region, was associated with a decline in FEV1 of 30 mL∙yr
-1
 or greater. In periostin, FAS I 384 
domains are thought to be primary binding sites to fibronectin, tenascin-C, and collagen V
21
, 385 
whereas the C-terminal region in its intact form may down-regulate the binding activity of 386 
periostin to these extracellular matrix proteins
21
. We therefore speculate that the minor A 387 
allele of rs9603226 might modify the binding activity at the C-terminal region and facilitate 388 
airway remodeling, particularly if the airway is in periostin enriched milieu. Further studies 389 
are needed to clarify if these SNPs are functional variants. 390 
The age of patients in this study appears to be older than in other Euro-American 391 
studies
6,7,14,18,20,23,25
. One reason for the age distribution would be the entry criteria of this 392 
study. Another reason would be explained by population aging including population with 393 
asthma in Japan. According to a patient survey by the Japanese Ministry of Health, Labour 394 
and Welfare in 2008, patients aged 70 to 74 years were the most frequent age group of adult 395 
patients with asthma
46
, which is still older than the average age of patients in this study.  396 
There are several limitations to the present study. First, since this study was 397 
observational in nature, ICS doses and numbers or types of controllers were not fixed during 398 
19 
 
the follow-up period. Controllers such as long-acting β2 agonists were not withdrawn at 399 
pulmonary function testing to evaluate function on daily medications, which may have 400 
resulted in the small average ΔFEV1, -7.8 mL‧yr
-1
. Meanwhile, averages of 16.2 401 
measurements of FEV1 and 8.0 years of follow-up were satisfactory for a longitudinal 402 
analysis of pulmonary function
47, and ΔFEV1 was normally distributed. Secondly, serum 403 
biomarkers were measured only once at enrollment, but the significant associations between 404 
POSTN gene polymorphisms and serum periostin levels or a decline in FEV1 of 30 mL∙yr
-1
 405 
or greater may circumvent the inherent insufficiency of single measurement of serum 406 
periostin. Thirdly, most of the clinical information, including smoking history and chronic 407 
sinusitis, was based on a self-completed questionnaire, which might be biased by recall 408 
memory. Despite these limitations, the current findings may provide directions for future 409 
research. 410 
In conclusion, serum periostin appears to be a useful biomarker that reflects the 411 
development of airflow limitation in patients on prolonged treatment with ICS. POSTN gene 412 




The authors would like to acknowledge Dr Nobuo Ohta, Department of 415 
Otolaryngology, Head and Neck Surgery, Yamagata University for fruitful discussion on 416 
periostin expression in nasal tissue of chronic sinusitis. The authors would also like to thank 417 
Ms Maki Futamata (Saga Medical School), Dr Guergana Petrova Stoyanoya, Dr Cui Shilei, 418 




1. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung 421 
function in asthma: an overview. J Allergy Clin Immunol 2005; 116:477-86; quiz 87. 422 
2. Niimi A, Matsumoto H, Takemura M, Ueda T, Chin K, Mishima M. Relationship of 423 
airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J 424 
Respir Crit Care Med 2003; 168:983-8. 425 
3. Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M, et al. Role of 426 
small airways in asthma: investigation using high-resolution computed tomography. J 427 
Allergy Clin Immunol 2006; 118:1019-25. 428 
4. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of 429 
ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-200. 430 
5. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. Eur Respir J 431 
1999; 13:904-18. 432 
6. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, Group SI. Severe 433 
exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 434 
2009; 179:19-24. 435 
7. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung 436 
function decline in asthma. Eur Respir J 2007; 30:452-6. 437 
8. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J 438 
Respir Crit Care Med 1994; 150:629-34. 439 
9. Ulrik CS, Backer V, Dirksen A. A 10 year follow up of 180 adults with bronchial 440 
asthma: factors important for the decline in lung function. Thorax 1992; 47:14-8. 441 
10. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with 442 
persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 443 
164:744-8. 444 
11. Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, et al. 445 
Polymorphisms of the ADAM33 gene are associated with accelerated lung function 446 
decline in asthma. Clin Exp Allergy 2004; 34:757-60. 447 
12. Koppelman GH, Sayers I. Evidence of a genetic contribution to lung function decline 448 
in asthma. J Allergy Clin Immunol 2011; 128:479-84. 449 
13. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. 450 
Genomewide association between GLCCI1 and response to glucocorticoid therapy in 451 
asthma. N Engl J Med 2011; 365:1173-83. 452 
14. Dijkstra A, Vonk JM, Jongepier H, Koppelman GH, Schouten JP, ten Hacken NH, et 453 
al. Lung function decline in asthma: association with inhaled corticosteroids, smoking 454 
and sex. Thorax 2006; 61:105-10. 455 
15. O'Byrne PM, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Effects 456 
of early intervention with inhaled budesonide on lung function in newly diagnosed 457 
22 
 
asthma. Chest 2006; 129:1478-85. 458 
16. Selroos O, Löfroos AB, Pietinalho A, Riska H. Asthma control and steroid doses 5 459 
years after early or delayed introduction of inhaled corticosteroids in asthma: a real-460 
life study. Respir Med 2004; 98:254-62. 461 
17. de Marco R, Marcon A, Jarvis D, Accordini S, Bugiani M, Cazzoletti L, et al. Inhaled 462 
steroids are associated with reduced lung function decline in subjects with asthma 463 
with elevated total IgE. J Allergy Clin Immunol 2007; 119:611-7. 464 
18. van Veen IH, Ten Brinke A, Sterk PJ, Sont JK, Gauw SA, Rabe KF, et al. Exhaled 465 
nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 466 
2008; 32:344-9. 467 
19. Levine SJ, Wenzel SE. Narrative review: the role of Th2 immune pathway modulation 468 
in the treatment of severe asthma and its phenotypes. Ann Intern Med 2010; 152:232-469 
7. 470 
20. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 471 
2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care 472 
Med 2009; 180:388-95. 473 
21. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel 474 
component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-475 
13 signals. J Allergy Clin Immunol 2006; 118:98-104. 476 
22. Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N, et al. Incorporation of 477 
tenascin-C into the extracellular matrix by periostin underlies an extracellular 478 
meshwork architecture. J Biol Chem 2010; 285:2028-39. 479 
23. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. 480 
Genome-wide profiling identifies epithelial cell genes associated with asthma and 481 
with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007; 482 
104:15858-63. 483 
24. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial 484 
cell-derived periostin in TGF-beta activation, collagen production, and collagen gel 485 
elasticity in asthma. Proc Natl Acad Sci U S A 2010; 107:14170-5. 486 
25. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a 487 
systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J 488 
Allergy Clin Immunol 2012; 130: 647-54. 489 
26. Standards for the diagnosis and care of patients with chronic obstructive pulmonary 490 
disease (COPD) and asthma. This official statement of the American Thoracic Society 491 
was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 492 
1987; 136:225-44. 493 
27. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma 494 
(GINA) 2010. Available from: Global Strategy for Asthma Management and 495 
23 
 
Prevention, Global Initiative for Asthma (GINA) 2010. Available from: 496 
http://www.ginasthma.org. 497 
28. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, et al. 498 
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. 499 
Eur Respir J 2011; 37:1119-27. 500 
29. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin 501 
promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 502 
2012; 122:2590-600. 503 
30.       Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl 504 
Acad Sci U S A 2003; 100:9440-5. 505 
31. Broekema M, Volbeda F, Timens W, Dijkstra A, Lee NA, Lee JJ, et al. Airway 506 
eosinophilia in remission and progression of asthma: accumulation with a fast decline 507 
of FEV1. Respir Med 2010; 104:1254-62. 508 
32. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. 509 
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 510 
2009; 360:973-84. 511 
33. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. 512 
Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98. 513 
34. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of 514 
interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, 515 
physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-88. 516 
35. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 517 
1999; 104:1001-6. 518 
36. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum 519 
and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 520 
2008; 121:685-91. 521 
37. Norris RA, Damon B, Mironov V, Kasyanov V, Ramamurthi A, Moreno-Rodriguez R, 522 
et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of 523 
connective tissues. J Cell Biochem 2007; 101:695-711. 524 
38. Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. 525 
Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal 526 
responses. Mucosal Immunol 2008; 1:289-96. 527 
39. Gordon ED, Sidhu SS, Wang ZE, Woodruff PG, Yuan S, Solon MC, et al. A protective 528 
role for periostin and TGF-β in IgE-mediated allergy and airway hyperresponsiveness. 529 
Clin Exp Allergy 2012; 42:144-55. 530 
40. Sehra S, Yao W, Nguyen ET, Ahyi AN, Tuana FM, Ahlfeld SK, et al. Periostin 531 
regulates goblet cell metaplasia in a model of allergic airway inflammation. J 532 
Immunol 2011; 186:4959-66. 533 
24 
 
41. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir 534 
J 2004; 24:822-33. 535 
42. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, et al. 536 
Effects of smoking cessation on lung function and airway inflammation in smokers 537 
with asthma. Am J Respir Crit Care Med 2006; 174:127-33. 538 
43. Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG. Allergic 539 
rhinitis and sinusitis in asthma: differential effects on symptoms and pulmonary 540 
function. Chest 2006; 130:429-35. 541 
44. Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic 542 
eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann 543 
Allergy Asthma Immunol 2005; 94:652-7. 544 
45. Ishida A, Ohta N, Suzuki Y, Kakehata S, Okubo K, Ikeda H, et al. Expression of 545 
Pendrin and Periostin in Allergic Rhinitis and Chronic Rhinosinusitis. Allergol Int 546 
2012; 61: 589-95. 547 
46. Japanese Society of Allergology, Asthma Guideline Committee. Asthma Prevention 548 
and Management Guidelines 2012. Tokyo: Kyowa Kikaku; 2012 (in Japanese) 549 
47. Wang ML, Gunel E, Petsonk EL. Design strategies for longitudinal spirometry 550 






Table 1. Contents of the self-completed questionnaire 555 
Asthma-related history    
 ・family history of asthma    
 ・age of asthma onset    
 ・history of pediatric asthma    
 ・history of admission due to asthma worsening or exacerbation 
 ・aspirin hypersensitivity    
 ・asthma deterioration at the working place   
      
Comorbidity or a history of the following diseases  
 ・allergic dermatitis  ・cardiovascular diseases including ischemic heart disease 
 ・allergic rhinitis  ・gastrointestinal diseases including GERD 
 ・seasonal rhinitis  ・collagen vascular diseases including rheumatoid arthritis 
 ・allergic conjunctivitis  ・diabetes mellitus  
 ・chronic sinusitis  ・pulmonary diseases other than asthma 
 ・other diseases including malignancy 
      
Lifestyle and environment    
 ・smoking history  ・a highway near the home  
 ・pet breeding  ・age at menopause  
 ・type of occupation     
      
Adherence to medication, sputum production, and exacerbations 
・How often do you forget to take inhaled corticosteroids or other medications? 
0: never, 1: seldom, 2: sometimes, 3: often, 4: always 
・How often do you produce sputum? 
0: never, 1: once in a few days, 2: every morning, 3: every morning and daytime 
・How often did you receive systemic steroids due to asthma exacerbations during the 
recent 6 months? 
0: never, 1: once, 2: twice or more 




Table 2. Patients’ characteristics  558 
Sex (males/ females), n  53 / 171 
 Age at enrollment, years 62.3 (13.7) 
Age at asthma onset, years   42.0 (19.0) 
Body mass index (kg/m
2
)  23.1 (3.5)  
 Smoking history (never), n 181 
 Atopic predisposition
*
 , % 70 
 Pediatric asthma (none/ recurrent/ persistent), % 81 / 8 / 11 
Disease duration, years  20.2 (14.5) 
ICS-untreated period, years  9.2 (13.1)  
ICS daily maintenance dose†, μg  525 (318) 
 Number of other controller medications, n  1.4 (1.2) 
 Treatment step (2/ 3/ 4/ 5)‡, %  16 / 27 / 49 / 8 
 Sputum production (0/ 1/ 2/ 3)§, % 54 / 20 / 8 / 18 
Asthma Control Test, points   22.6 (3.5)  
History of admission due to asthma, n (%)  78 (35) 
Allergic rhinitis, n (%)  129 (58) 
 Chronic sinusitis, n (%)  65 (29) 
 Blood neutrophils, %  60.1 (10.0)  
      eosinophils, %  5.2 (4.9)  
Serum IgE, IU/mL  180 (0 - 16000)  
       periostin, ng/mL  92.8 (38.4)  
       high sensitivity C-reactive protein, mg/L  1341 (3147)  
       eosinophil cationic protein, μg/L  15.1 (29.3)  
 FEV1 at the first measurement, L
¶  2.11 (0.69) 
 %predicted FEV1 at the first measurement, %  91.9 (19.2) 
 FEV1/ FVC at the first measurement, %  73.9 (9.8) 
 FEV1 at enrollment, L  2.04 (0.73) 
 %predicted FEV1 at enrollment, %  97.4 (22.2) 
 FEV1/ FVC at enrollment, %  72.2 (10.0) 
 Reversibility at enrollment, %#   3.8 (6.0) 
Data at enrollment are presented unless otherwise stated. Data are expressed as means (SD) except for median 559 
(range) for serum IgE. 
*
Considered atopic when one or more specific IgE antibodies against cat or dog dander, 560 
weed, grass, or Japanese cedar pollens, moulds, or house dust mite were positive.
 †Equivalent to fluticasone 561 
propionate.
 ‡according to the Global Initiative for Asthma 2010 guideline
27
.§0 = never, the details are shown in 562 
Table 1. ¶The first pulmonary function test was performed at least one year after the commencement of ICS 563 
treatment and at 25 years of age or older. 
#
n = 206, airway reversibility to 200 μg of inhaled salbutamol.564 
27 
 
Table 3. Estimated effects of clinical indices and biomarkers on ΔFEV1 565 
 Estimates  95% C.I. p value 
Smoking history, ex vs. never -8.48 -20.2, 3.27 0.16 
Atopic predisposition  -1.10  -6.29, 4.09 0.68 
Disease duration, years  -4.79 -18.4, 8.86 0.56 
ICS-untreated period, years  0.10 -0.24, 0.45 0.65 
ICS daily maintenance dose, μg  -0.01 -0.03, 0.001 0.07 
Number of other controller medications, n -0.36 -4.21, 3.49 0.86 
Adherence to medication, incomplete vs. complete
*
 -4.56 -9.08, -0.04 0.05 
Treatment step, 5 vs. 2-4†  -7.77 -15.7, 0.13 0.05 
Sputum production, never vs. others‡ 0.99 -3.53, 5.51 0.67 
Asthma Control Test, points  1.53 0.29, 2.77 0.02 
History of admission due to asthma -4.49 -9.45, 0.46 0.08 
Aspirin hypersensitivity -6.52 -20.0, 6.98 0.34 
Asthma deterioration at the working place -12.2 -54.4, 30.0 0.57 
Allergic rhinitis  -1.21 -5.88, 3.45 0.61 
Allergic dermatitis  4.51 -1.51, 10.5 0.14 
Chronic sinusitis  -10.1 -19.8, -0.27 0.04 
Ischemic heart disease 3.41 -16.6, 23.4 0.74 
Hypertension -3.79 -9.12, 1.53 0.16 
Dyslipidemia -3.67 -9.42, -2.06 0.21 
Diabetes mellitus -8.03 -15.4, -0.67 0.03 
Gastro-esophageal reflux disease -3.85 -9.89, 2.19 0.21 
Malignancy  -3.44 -26.0, 19.1 0.76 
Post-menopause  5.05 -14.2, 24.3 0.60  
Pet breeding  -0.28 -12.6, 12.0 0.96 
Log blood neutrophils, % -7.40 -69.1, 54.3 0.81 
         eosinophils, % -0.67 -1.60, 0.27 0.16 
Log serum IgE, IU/mL -2.85 -9.74, 4.04 0.42 
         periostin, ng/mL -29.1 -56.2, -1.97 0.04 
         high sensitivity C-reactive protein, mg/L -1.88 -9.85, 6.10 0.64 
         eosinophil cationic protein, μg/L -4.47 -15.7, 6.81 0.44 
Periostin group, high vs. low§ -6.96 -11.4, -2.51 0.002 
    
Estimated effects were adjusted by sex, height, age at enrollment, and FEV1 at the first measurement.
 * “Complete”, when patients answered 566 
that they never forgot to take ICS or other medications; “incomplete”, the remaining cases. †according to the Global Initiative for Asthma 567 
2010 guideline27. ‡The details are shown in Table1. §Patients were stratified into two groups according to their serum periostin levels: high ≥ 568 
95 ng/mL, low < 95 ng/mL. ICS: inhaled corticosteroids, C.I.: confidence interval569 
28 
 
Table 4. Estimated effects of clinical indices and serum periostin on a decline in FEV1 of 570 
30 mL∙yr-1 or greater 571 
 Univariate analysis  Multivariate analysis  
 Estimates  95% C.I. p value Estimates  95% C.I. p value 
Treatment step, 5 vs. 2-4
*
  1.63 0.51, 2.60 0.004  1.24 0.078, 2.30 0.04 
History of admission due to asthma 1.09 0.37, 1.90 0.003 0.70 -0.11, 1.50 0.09 
ICS daily maintenance dose, μg  0.001 0.00, 0.002 0.01 -   
Chronic sinusitis  0.82 0.11, 1.53 0.03 0.61 -0.15, 1.37 0.12 
Smoking history, ex vs. never 0.87 -0.002, 1.74 0.05 0.98 0.030, 1.93 0.04 
Log serum periostin, ng/mL 2.96 0.78, 5.13 0.008 -   
Periostin group, high vs. low† 1.03 0.33, 1.72 0.004 0.87 0.11, 1.63 0.03 
Estimated effects were adjusted by sex, height, age at enrollment, and FEV1 at the first measurement.   572 
*






Patients were stratified into two groups according to their serum periostin levels: high ≥ 95 ng/mL, low < 574 
95 ng/mL. ICS: inhaled corticosteroids, C.I.: confidence interval 575 
ICS daily maintenance dose was excluded from multivariate analysis because of its strong correlation with 576 




Table 5. Frequencies of 3 tag SNPs and analysis results using dominant and recessive models 579 
for serum periostin levels and frequency of rapid decliners* 580 
     
Serum periostin levels 
Frequency of  
rapid decliners      
     p value p value 
Tag SNP Genotype n (%) Allelic n (%) Dominant† Recessive‡ Dominant† Recessive‡ 
rs1028728  AA  164 (74)  A  383 (86) 
0.40  0.46 0.17 0.14   AT  55 (25)  T  63 (14) 
  TT  4 (2)   
rs3829365  GG  113 (51)  G  316 (71) 
0.003 0.70  0.40  0.33   GC  90 (40)  C  130 (29) 
  CC  20 (9)   
rs9603226  GG  107 (48)  G  311 (70) 
0.80  0.33 0.01 0.81   AG  97 (44)  A  135 (30) 
  AA  19 (9)   
*
 defined as patients who showed a decline in FEV1 of 30 mL∙yr
-1




 Assuming that heterozygotes have the same increased risk as minor homozygous genotypes. 582 




Figure legends 585 
Figure 1. Three tag SNPs that determine 4 major haplotypes of the POSTN gene and 586 
haplotype frequencies in the Japanese population are presented. 587 
*at intron 66 bp upstream of exon 21 588 
 589 
Figure 2. Relationships between serum periostin levels and blood eosinophil counts (left) or 590 
serum IgE levels (right). 591 












































Serum total IgE* 
r = 0.29 



















0 10 100 
r = 0.30 
p = 0.0001 
Figure 2. 
Online Repository 1 
Increased periostin associates with greater airflow limitation in patients receiving 2 
inhaled corticosteroids 3 
  4 
Yoshihiro Kanemitsu MD*
1,2
, Hisako Matsumoto MD, PhD*
1,2
, Kenji Izuhara 5 
MD,PhD
3
, Yuji Tohda MD, PhD
2,4
, Hideo Kita MD, PhD
2,5
, Takahiko Horiguchi MD, 6 
PhD
2,6
, Kazunobu Kuwahara MD, PhD
2,6
, Keisuke Tomii MD, PhD
2,7
, Kojiro Otsuka 7 
MD, PhD
1,2,7
, Masaki Fujimura MD, PhD
2,8
, Noriyuki Ohkura MD
2,8
, Katsuyuki Tomita 8 
MD, PhD
2,4
, Akihito Yokoyama MD, PhD
2,9
, Hiroshi Ohnishi MD, PhD
2,9
, Yasutaka 9 
Nakano MD, PhD
2,10
, Tetsuya Oguma MD, PhD
2,10





, Isao Ito MD, PhD
1
, Tsuyoshi Oguma MD
1





, Toshiyuki Iwata MD
1
, Yumi Izuhara MD
1
, Junya Ono BS
12
, 12 
Shoichiro Ohta MD, PhD
13
, Mayumi Tamari MD, PhD
14
, Tomomitsu Hirota DDS, 13 
PhD
14
, Tetsuji Yokoyama MD, PhD
15
, Akio Niimi MD, PhD
1,2,16
 and Michiaki Mishima 14 
MD, PhD
1,2
.   15 
Affiliations 16 
1
 Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 17 
Kyoto, Japan. 18 
2
 Kinki Hokuriku Airway disease Conference (KiHAC) 19 
3
 Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga 20 
Medical School, Saga, Japan. 21 
4 
Department of Respiratory Medicine and Allergology, Faculty of Medicine, Kinki 22 
University, Osaka, Japan. 23 
5
 Department of Respiratory Medicine, Takatsuki Red Cross Hospital, Osaka, Japan. 24 
6
 Department of Respiratory Internal Medicine, Fujita Health University Second 25 
Educational Hospital, Aichi, Japan. 26 
7
 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 27 
Hyogo, Japan. 28 
8
 Department of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa 29 
University Graduate School of Medicine, Kanazawa, Japan. 30 
9
 Department of Hematology and Respiratory Medicine, Kochi University, Kochi, 31 
Japan. 32 
10
 Division of Respiratory Medicine, Department of Internal Medicine, Shiga University 33 
of Medical Science, Shiga, Japan. 34 
11
 Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan. 35 
12 
Shino-Test Corporation, Kanagawa, Japan. 36 
13
 Department of Laboratory Medicine, Saga Medical School, Saga, Japan. 37 
14
 Laboratory for Respiratory Diseases, Center for Genomic Medicine, RIKEN, 38 
Yokohama, Kanagawa, Japan. 39 
15
 Department of Health Promotion, National Institute of Public Health, Wako, Saitama, 40 
Japan 41 
16 
Department of Medical Oncology and Immunology, Nagoya City University School 42 
of Medical Sciences, Aichi, Japan. 43 
 44 
*YK and HM similarly contributed to this study. 45 
 46 
Correspondence should be addressed to Hisako Matsumoto M.D., Ph.D.,  47 
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 48 
53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.  49 




     Patients with asthma were recruited from nine institutions belonging to the Kinki 54 
Hokuriku Airway disease Conference where asthma specialists manage patients, 55 
including six university hospitals, two satellite general hospitals, and one satellite clinic. 56 
Asthma was diagnosed according to the American Thoracic Society criteria
E1
 on the 57 
basis of a history of recurrent episodes of wheezing and chest tightness with or without 58 
cough and documented airway reversibility to a bronchodilator or hyper-responsiveness 59 
to inhaled methacholine. From September 2009 to December 2011, patients were 60 
enrolled if they had received ICS treatment for 4 years or more, undergone three or 61 
more pulmonary function tests when they were stable, and were free from exacerbations 62 
for at least one month. The first pulmonary function test was performed at least one year 63 
after the commencement of ICS treatment and at 25 years of age or older. Patients who 64 
had smoked more than 10 pack-years, smoked in the past one year, or had other 65 
pulmonary diseases were excluded. 66 
 67 
Self-completed questionnaire and clinical indices 68 
 The self-completed questionnaire was composed of 4 major items, as presented 69 
in Table 1. 70 
 Adherence to ICS or other medications, frequency of sputum production, and 71 
requirement for systemic corticosteroids during the last 6 months were graded as shown 72 
in Table 1. The Asthma Control Test (ACT)™ was also scored. Duration of ICS 73 
treatment and details on medication at enrollment were recorded from medical charts by 74 
patients’ physicians. The treatment step at enrollment was determined according to the 75 




Measurement of systemic biomarkers 78 
Blood eosinophil and neutrophil counts, and serum levels of total 79 
immunoglobulin E (IgE) (ImmunoCAP
®
 total IgE, Phadia K.K., Tokyo, Japan), specific 80 
IgE against common inhaled allergens (ImmunoCAP
®
 specific IgE), eosinophil cationic 81 
protein (ECP) (ImmunoCAP
®
 ECP), high sensitivity C-reactive protein (hsCRP) 82 
(CardioPhase
®
 hsCRP, Siemens Healthcare Diagnostics K.K., Tokyo, Japan), and 83 
periostin were determined. 84 
Serum periostin levels were measured using an enzyme-linked immunosorbent 85 
assay at Shino-test (Kanagawa, Japan), as described previously
E3
. Briefly, two rat 86 
anti-human periostin monoclonal antibodies (SS18A and SS17B) were used. SS18A and 87 
SS17B are antibodies against the first and fourth FAS I domains, respectively. Intra- and 88 
inter-assay coefficients of variation ranged from 1.31% to 2.54% and 1.49% to 2.01%, 89 
respectively.  90 
 91 
Haplotype analysis, DNA extraction, and genotyping of the POSTN gene 92 
A total of 47 single-nucleotide polymorphisms (SNPs) in the region of the 93 
POSTN gene and its upstream, total 39 kb, was captured in the HapMap Japanese data 94 
set with minor allele frequencies > 0.10. Pairwise tagging was performed at r
2
 > 0.8 95 
using a tagger in Haploview 4.2 software. Haplotype analysis identified 4 major 96 
haplotypes and 2 minor haplotypes. Two minor haplotypes were grouped into the closest 97 
major haplotype, and 3 tag SNPs that determined the 4 haplotypes were identified 98 
(Figure 1). These 3 tag SNPs were located at promoter region (rs1028728), 5’UTR 99 
region (rs3829365), and at intron 66 bp upstream of exon 21 (rs9603226). The 100 
frequencies of the minor alleles in the Japanese population were 0.136 (rs1028728), 101 
0.278 (rs3829365), and 0.330 (rs9603226). 102 
Genomic DNA was isolated from blood cells using a QIAamp DNA Blood Mini 103 
Kit (Qiagen, Tokyo, Japan). SNPs were genotyped using a Taqman genotyping assay 104 
according to the manufacturer’s instructions (Applied Biosystems, Tokyo, Japan) and 105 
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Figure legends 124 
 125 
Figure E1. The distribution of ΔFEV1 in the study population 126 
 127 
Figure E2. ROC curve analysis of serum periostin levels comparing asthmatic patients 128 
and healthy subjects, in which the cutoffs of 95 ng/mL, 80 ng/mL, 92 ng/mL, and 100 129 





























AUC = 0.908 
80 ng/mL 
92 ng/mL 
100 ng/mL 
95 ng/mL 
Figure E2. 
